John Reynolds
www.mendeley.com
0000-0002-8825-8625
Alfred Health
67 papers found
Refreshing results…
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG
Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients
Patient activation intervention to facilitate participation in recovery after total knee replacement (MIME): a cluster randomised cross-over trial
A Capacity Building Program to Improve the Self-Efficacy of Key Workers to Support the Well-Being of Parents of a Child With a Disability Accessing an Early Childhood Intervention Service: Protocol for a Stepped-Wedge Design Trial
Restricted cell cycle is essential for clonal evolution and therapeutic resistance of pre-leukemic stem cells
Minimal Sex-Differential Modulation of Reactivity to Pathogens and Toll-Like Receptor Ligands following Infant Bacillus Calmette–Guérin Russia Vaccination
Microbiota of little penguins and short-tailed shearwaters during development
ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure
Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors
Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma
Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease
A Multicentre, Single Arm, Open Label Study Evaluating the Efficacy and Safety of Eltrombopag in Patients With Severe Persistent Immune Thrombocytopenic Purpura (Itp) Within Six Months of Diagnosis
Pomalidomide Alone or in Combination With Low Dose Dexamethasone as Maintenance Following Induction With Pomalidomide and Low Dose Dexamethasone in Relapsed and Refractory Myeloma (Allg Mm14)
Sex-Differential Non-Vaccine-Specific Immunological Effects of Diphtheria-Tetanus-Pertussis and Measles Vaccination
TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy
Adequate trough infliximab levels after induction therapy may be associated with increased rates of sustained clinical response in Crohn's disease
Missing publications? Search for publications with a matching author name.